Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744279 | 0.89 | AHCY (0.47) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL177772 | 0.88 | AHCY (0.61) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL28901883 | 0.88 | AHCY (0.61) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL29877256 | 0.88 | AHCY (0.61) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL1068915 | 0.85 | AHCY (0.60) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL8661748 | 0.84 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL8661561 | 0.84 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL397800 | 0.83 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL31680251 | 0.83 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL22326785 | 0.82 | PRMT5 (0.64) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| EP-1272897-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-6555545-B2 | Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents | NEW YORK UNIVERSITY | 2003-04-29 | — | — | US | claimed |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | NEW YORK UNIVERSITY | 2002-01-03 | — | — | US | claimed |
| US-5424297-A | Adenosine dextran conjugates | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1995-06-13 | — | — | US | claimed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12227578-B2 | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action | THE BROAD INSTITUTE, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-9414901-B2 | Drug-eluting stents for adenosine receptor modulation | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | SITKOVSKY MICHAIL V (US) | 2013-12-05 | — | — | US | disclosed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | disclosed |
| US-20110144027-A1 | PHARMACEUTICAL COMPOSITIONS FOR PROMOTING WOUND HEALING | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2011-06-16 | — | — | US | disclosed |
| US-5773423-A | XANTHINE RIBOSIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5424297-A | Adenosine dextran conjugates | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1995-06-13 | — | — | US | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | ADORA2A, ADORA3, ADORA1 | AHCY 382/4885HIF1A 689/4885TMEM97 1156/4885 |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | ADORA2A, ADORA1, ADORA2B | AHCY 44/4885HIF1A 920/4885TMEM97 1913/4885 |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | AHCY 3973/4885HIF1A 1172/4885TMEM97 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.